Evidence map›Paper›PMID 26742084›Full record

ArticleMetabolites2016

Metabolic Flux Distribution during Defatting of Steatotic Human Hepatoma (HepG2) Cells.

Gabriel Yarmush, Lucas Santos, Joshua Yarmush, Srivathsan Koundinyan, Mubasher Saleem, Nir I Nativ, Rene S Schloss, Martin L Yarmush, Timothy J Maguire, Francois Berthiaume

Abstract read
In one paragraph

Article in Metabolites, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. A Review of Defatting Strategies for Non-Alcoholic Fatty Liver Disease.International journal of molecular sciences · 2022
    Review
  3. Defatting strategies in the current era of liver steatosis.JHEP reports : innovation in hepatology · 2021
    Review
  4. Review
  5. Article
  6. Review
  7. Manipulation of Lipid Metabolism During Normothermic Machine Perfusion: Effect of Defatting Therapies on Donor Liver Functional Recovery.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2019
    Article
  8. Article
  9. Clinical Hepatocyte Transplantation: What Is Next?Current transplantation reports · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Gabriel YarmushDepartment of Biomedical Engineering, Rutgers University, Piscataway, NJ 08854, USA. gabriel.yarmush@gmail.com.
Lucas SantosDepartment of Biomedical Engineering, Rutgers University, Piscataway, NJ 08854, USA. lucasvcsantos2@gmail.com.
Joshua YarmushDepartment of Biomedical Engineering, Rutgers University, Piscataway, NJ 08854, USA. josh.yarmush@gmail.com.
Srivathsan KoundinyanDepartment of Biomedical Engineering, Rutgers University, Piscataway, NJ 08854, USA. srivaths1992@gmail.com.
Mubasher SaleemDepartment of Biomedical Engineering, Rutgers University, Piscataway, NJ 08854, USA. mubasher.saleem1@gmail.com.
Nir I NativDepartment of Biomedical Engineering, Rutgers University, Piscataway, NJ 08854, USA. nirnativ1@hotmail.com.
Rene S SchlossDepartment of Biomedical Engineering, Rutgers University, Piscataway, NJ 08854, USA. schloss@soemail.rutgers.edu.
Martin L YarmushDepartment of Biomedical Engineering, Rutgers University, Piscataway, NJ 08854, USA. yarmush@rci.rutgers.edu.
Timothy J MaguireDepartment of Biomedical Engineering, Rutgers University, Piscataway, NJ 08854, USA. timjm@rci.rutgers.edu.
Francois BerthiaumeDepartment of Biomedical Engineering, Rutgers University, Piscataway, NJ 08854, USA. fberthia@rci.rutgers.edu.

Funding

UMDNJ TRAINING GRANT IN BIOTECHNOLOGYT32GM008339 · NIGMS · RUTGERS THE ST UNIV OF NJ NEW BRUNSWICK · PI YARMUSH, MARTIN L · 1989 to 2019
$6.1M
Metabolic Engineering for Improved Liver FunctionR01DK059766 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI YARMUSH, MARTIN L · 2002 to 2011
$3.5M
Merging Innovation, Translational Medicine, and Entrepreneurship in Biomedical EnR25EB014769 · NIBIB · RUTGERS, THE STATE UNIV OF N.J. · PI YARMUSH, MARTIN L · 2012 to 2016
$216k
NIBIB NIH HHS R25 EB014769NIDDK NIH HHS R01 DK059766NIGMS NIH HHS T32 GM008339
6 · The paper itself

Abstract

Methods that rapidly decrease fat in steatotic hepatocytes may be helpful to recover severely fatty livers for transplantation. Defatting kinetics are highly dependent upon the extracellular medium composition; however, the pathways involved are poorly understood. Steatosis was induced in human hepatoma cells (HepG2) by exposure to high levels of free fatty acids, followed by defatting using plain medium containing no fatty acids, or medium supplemented with a cocktail of defatting agents previously described before. We measured the levels of 28 extracellular metabolites and intracellular triglyceride, and fed the data into a steady-state mass balance model to estimate strictly intracellular fluxes. We found that during defatting, triglyceride content decreased, while beta-oxidation, the tricarboxylic acid cycle, and the urea cycle increased. These fluxes were augmented by defatting agents, and even more so by hyperoxic conditions. In all defatting conditions, the rate of extracellular glucose uptake/release was very small compared to the internal supply from glycogenolysis, and glycolysis remained highly active. Thus, in steatotic HepG2 cells, glycolysis and fatty acid oxidation may co-exist. Together, these pathways generate reducing equivalents that are supplied to mitochondrial oxidative phosphorylation.

Indexed as

beta-oxidationdefattingfatty liverhepatocytesliver transplantationmass balancessteatosis

Identifiers

PMID26742084
PMCPMC4812330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.